Barclays raised the firm’s price target on Blueprint Medicines to $58 from $46 and keeps an Equal Weight rating on the shares following the “strong beat” in Q3.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BPMC:
